Ozone high dose therapy (OHT) improves mitochondrial bioenergetics in peripheral blood mononuclear cells
König B, Lahodny J. Translational Medicine Communications, 2022.
- Study type
- Case series
- People studied
- 6 people
- Published
- 2022, Translational Medicine Communications
- Identifiers
- PMID 35880042, DOI 10.1186/s41231-022-00123-7
What the authors reported
In 6 patients given two 10-pass ozone high-dose therapy (OHT) sessions within a week, a laboratory bioenergetic health index in blood cells improved, driven mainly by increased mitochondrial reserve capacity.
What limits this result
Six patients, no control group; a laboratory biomarker rather than a symptom or clinical outcome, co-authored by the technique's own developer. The abstract does not state a specific cumulative ozone dose in micrograms.
How ozone acts on blood and cells, how blood filters work, and studies that measure markers in the blood rather than how patients fare. None of these shows whether EBO2 helps patients. One study rarely settles a medical question; our guides weigh each paper against the rest of the evidence.
Where we cite this study
EBO2 (EBOO) vs 10-Pass Ozone and MAH: What Is Actually Different
How EBO2 (EBOO), 10-pass ozone, and major autohemotherapy differ in blood volume, filtration, cost, and what the evidence actually supports.